Abbott Laboratories 8-K

EarningsGuidance reaffirmedImpairment / chargeLegal / investigation

Electrophysiology led sales growth as legal settlements weighed on GAAP earnings; FY2026 adjusted EPS guidance narrowed to $5.50–$5.55.

Filed 2026-10-21 07:36 ET

Summary

Q3 2026 results with Q4 and FY2026 guidance. Net sales rose 14.5% reported and 7.0% on a comparable basis; GAAP diluted EPS was $0.53 and adjusted diluted EPS was $1.42. Comparable growth was broad-based, while GAAP earnings included substantial specified charges; Abbott also reaffirmed the midpoint of FY2026 adjusted EPS guidance and tightened its range.

Key Figures

Metric Q3 2026 9M 2026
Revenue $13.0B, +14.5% Y/Y $36.8B, +11.9% Y/Y
Gross margin 50.3%, vs 51.7% 51.7%, vs 52.4%
Gross margin, non-GAAP 57.2%, vs 55.8% 57.2%, vs 56.6%
Operating earnings $1.36B, -34.0% Y/Y $4.40B, -24.2% Y/Y
Net earnings $920M, -44.1% Y/Y $2.93B, -38.4% Y/Y
Net earnings, non-GAAP $2.48B, +8.7% Y/Y $6.79B, +5.9% Y/Y
Diluted EPS $0.53, -43.6% Y/Y $1.67, -38.1% Y/Y
Diluted EPS, non-GAAP $1.42, +9.2% Y/Y $3.88, +6.3% Y/Y
  • Sales growth leaders included electrophysiology, up 15.5% on a comparable basis, and worldwide pediatric nutrition, up 8.7%.
  • Q3 specified items totaled $1.689B before tax and $1.557B after tax, including $841M of intangible amortization and ≈$670M related to legal settlements.
  • Quarterly dividend of $0.63 per share, declared 9/17/2026; payable 11/16/2026 to holders of record 10/15/2026.

Guidance

Metric Period Guidance Prior Direction
Comparable sales growth FY2026 ≈6.0% — —
Adjusted diluted EPS, non-GAAP FY2026 $5.50-$5.55 — Tightened; midpoint reaffirmed
Adjusted diluted EPS, non-GAAP Q4 2026 $1.62-$1.67 — —

Investor Takeaways

  • Track Q4 adjusted diluted EPS against the $1.62-$1.67 outlook and FY2026 comparable sales growth against ≈6.0%.

Was this summary useful?

The summary is written by an AI model reading the filing.

Model 005 · prompt v95 · 2026-10-21 14:33:19Z

Feedback